Brief: Paladin Phase 4 Study Confirms Safety Of Durable Iluvien Treatment And Reduces Burden Of Care For DME Patients
26/07/2022 13:21
July 26 (Reuters) - Alimera Sciences Inc ALIM.O :
* PALADIN PHASE 4 STUDY CONFIRMS SAFETY OF DURABLE ILUVIEN®
TREATMENT AND REDUCES BURDEN OF CARE FOR DME PATIENTS
* ALIMERA SCIENCES INC - DATA VERIFY THAT ILUVIEN PROVIDES
PHYSICIANS WITH A MUCH-NEEDED TOOL FOR SAFE AND DURABLE
TREATMENT OF DME
Source text for Eikon: ID:nGNX1CMd4G
Further company coverage: ALIM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alimera Sciences
See all newsBrief: ANI Pharmaceuticals And Alimera Sciences Announce Closing Date Of Merger
Brief: Ani Pharmaceuticals Provides Update On Closing Of Acquisition Of Alimera Sciences
U.S. STOCKS ON THE MOVE-JPMorgan, automakers, energy firms
U.S. STOCKS ON THE MOVE-Arrowhead Pharma, Boeing, Centessa Pharma
Brief: Alimera Sciences Files Lawsuit To Compel ANI To Close Merger